Related Experiment Video
Updated: Mar 19, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Emerging Artemisinin Partial Resistance in Southern Africa
Rosario Martinez-Vega1, Deus S Ishengoma2,3, Roly Gosling1,4
1Department of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom.
None:
A new focus of probable artemisinin-partial resistance (ART-R) has been identified in southern Africa, driven by the P441L mutation in the Plasmodium falciparum Kelch13 gene. This emerging cross-border cluster across Angola, Namibia, and Zambia represents the fourth major ART-R focus identified in Africa, adding to the previously reported foci in East Africa and the Horn of Africa. Findings from three new studies reveal 7.3%, 33%, and 47% prevalence of P441L in specific sites in Angola, Namibia, and Zambia, respectively. The Genomics of Malaria in the Elimination 8 project enabled harmonized, real-time molecular surveillance across five countries, providing actionable data for national malaria programs. Given past failures to contain chloroquine and sulfadoxine-pyrimethamine resistance, a timely response is critical. We recommend immediate treatment policy shifts, expanded surveillance, and regional coordination to prevent the spread of ART-R. This Perspective calls on global health actors to act decisively while resistance remains geographically limited.

